Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, Soo Young | - |
dc.contributor.author | Yoo, Sung Hwan | - |
dc.contributor.author | Chang, Hye Young | - |
dc.contributor.author | Kim, Sora | - |
dc.contributor.author | Lee, Jung Il | - |
dc.contributor.author | Lee, Kwan Sik | - |
dc.contributor.author | Cho, Young Youn | - |
dc.contributor.author | Kim, Hyung Joon | - |
dc.contributor.author | Lee, Hyun Woong | - |
dc.date.accessioned | 2023-10-18T02:40:37Z | - |
dc.date.available | 2023-10-18T02:40:37Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.issn | 1365-2893 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/68095 | - |
dc.description.abstract | HBeAg seroconversion is an important treatment endpoint. We aimed to identify predictors of seroconversion using serum HBsAg and hepatitis B core-related antigen (HBcrAg) in HBeAg-positive patients treated with nucleos(t)ide analogs (NAs). Data and samples from 70 HBeAg-positive patients treated with entecavir or tenofovir between January 2007 and December 2017 were retrospectively analysed. The mean follow-up period was 11 years. The predictive power for HBeAg seroconversion of HBcrAg levels at baseline and 2 years after antiviral therapy was determined using receiver operating curve analysis. Twenty-one patients (30%) achieved HBeAg seroconversion at a mean of 28 (range, 12-84) months after antiviral treatment. The median baseline HBcrAg and HBsAg levels were 6.9(5.7-7.0) vs. 5.8(5.5-6.5) log(10)U/mL (p = .006), 4.9(4.5-5.1) vs. 4.5(4.1-5.0) log(10)IU/mL (p = .044) in the no seroconversion group and seroconversion group, respectively. In the multivariate analysis, the serum HBcrAg levels at baseline and 2 years after antiviral therapy were predictive factors for HBeAg seroconversion ([HR]; 0.326; [CI], 0.111-0.958; p = .042 and HR, 0.4555; CI, 0.211-0.984; p = .045). HBcrAg levels <= 6.5log(10)U/mL at baseline and <= 5.3log(10)U/mL at 2 years after antiviral therapy had sensitivities of 53.1% and 69.8%, specificities of 95.2% and 70.6%, positive predictive values of 82.6% and 50.0%, and negative predictive values of 82.6% and 84.5%, respectively, with AUROCs of 0.712 (95%CI, 0.596-0.830) and 0.745 (95%CI, 0.599-0.891) for predicting HBeAg seroconversion. In chronic hepatitis B patients treated with NAs, HBcrAg levels <= 6.5log(10)U/mL at baseline and <= 5.3log(10)U/mL at 2 years after antiviral therapy were useful predictive factors of HBeAg seroconversion. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/jvh.13765 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, v.30, no.1, pp 39 - 45 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000881872700001 | - |
dc.identifier.scopusid | 2-s2.0-85142084056 | - |
dc.citation.endPage | 45 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 39 | - |
dc.citation.title | JOURNAL OF VIRAL HEPATITIS | - |
dc.citation.volume | 30 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | hepatitis B | - |
dc.subject.keywordAuthor | hepatitis B core-related antigen | - |
dc.subject.keywordAuthor | hepatitis B e antigen seroconversion | - |
dc.subject.keywordAuthor | hepatitis B surface antigen | - |
dc.subject.keywordAuthor | nucleos(t)ide analog | - |
dc.subject.keywordPlus | CORE-RELATED ANTIGEN | - |
dc.subject.keywordPlus | CLOSED CIRCULAR DNA | - |
dc.subject.keywordPlus | NUCLEOS(T)IDE ANALOGS | - |
dc.subject.keywordPlus | VIRUS GENOTYPES | - |
dc.subject.keywordPlus | SURFACE-ANTIGEN | - |
dc.subject.keywordPlus | MARKER | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | INFECTION | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.